Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
about
Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Identification of Clinically A ...... hibitor-Resistant Lung Cancer.
@en
Identification of Clinically A ...... hibitor-Resistant Lung Cancer.
@nl
type
label
Identification of Clinically A ...... hibitor-Resistant Lung Cancer.
@en
Identification of Clinically A ...... hibitor-Resistant Lung Cancer.
@nl
prefLabel
Identification of Clinically A ...... hibitor-Resistant Lung Cancer.
@en
Identification of Clinically A ...... hibitor-Resistant Lung Cancer.
@nl
P2093
P2860
P356
P1476
Identification of Clinically A ...... hibitor-Resistant Lung Cancer.
@en
P2093
Christy Wing-Sum Tong
Hongjian Li
Kenneth Kin-Wah To
Kwong-Sak Leung
Man-Hon Wong
P2860
P356
10.3389/FONC.2017.00288
P577
2017-11-29T00:00:00Z